Search

The authors reflect on the potential of intentional drug development by citing the results of a phase three randomized controlled trial on the effectiveness of ritonavir and nirmatrelvir as treatment against SARS-CoV-2 infection in COVID-19 unvaccinated patients. Based on the results, the combination drug was linked with mild dysgeusia and diarrhea, but it is effective against COVID-19.

The article presents the discussion on suffering relatively low Covid-19 vaccine coverage. Topics include immunity resulting from either vaccination or previous infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); and suggesting the possibility of a high prevalence of underlying seropositivity due to previous infection.

An editorial is presented on various studies regarding the use of viruses to treat diseases. Topics discussed include the potential use of viruses to change the course of cancer, the capability of oncolytic viruses to infect or kill tumor cells, and the study by A. Desjardins and colleagues on the use of an engineered poliovirus, targeting glioblastoma.

An introduction is presented in which the authors discuss articles within the issue on topics such as the duration of detection of Ebola virus by polymerase-chain-reaction assay and the randomized controlled trial of standard of care for Ebola infection.

The article discusses that rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the lack of known effective treatments for coronavirus disease 2019 have caused an unprecedented situation for patients and clinicians regimens. It mentions that pharmacologic treatments that have generated substantial interest: regimens based on remdesivir, hydroxychloroquine and lopinavir.

The article describes the case of a 60-year-old male renal transplant recipient who suffered from diabetic ketoacidosis and renal insufficiency as well as mental-status changes. The patient was suffering from chronic respiratory problems until two months before he got admitted to a hospital due to somnolence, increasing fatigue and intermittent mild confusion. It discusses the development of hypoattenuation in the posterior right lentiform nucleus in the brain of the patient.

The article discusses group of researchers led by Cao B. have performed an urgent randomized clinical trial of the efficacy of lopinavir-ritonavir drugs in patients with Covid-19 in Wuhan, China. It mentions that lopinavir-ritonavir does not seem to be highly effective in patients with Covid-19; and also mentions that lopinavir is not particularly potent against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

An editorial is presented on the "Take" as a Biomarker. Topics include inoculation of smallpox vaccine and formation of a pox-like scar at the vaccination site; risk of live vaccinia virus for local infection; and attenuated virus, Modified vaccinia Ankara (MVA's) safety in weak immune systems including cancer, human immunodeficiency virus (HIV) infection, and skin conditions.

The authors argue that the value of intensive fluid management and care is the most important take-home message from the case reports of Ebola virus disease (EVD) patients outside Africa. They say that it will be very hard to examine the contribution of a drug without comparative trials unless a new drug is profoundly effective. They add that the benefits of routine care like intravenous fluid and electrolyte support should be brought to all patients.

The article focuses on the implications for U.S. emergency use authorizations following the end of a declared public health emergency (PHE). Topics include the authority granted to U.S. public health agencies under section 319 of the Public Health Service Act and section 564 of the Federal Food, Drug, and Cosmetic Act for emergencies; and the Food and Drug Association's decision-making process and evidentiary standard for issuing emergency use authorizations during the COVID-19 pandemic.

The author reflects on the prevention of Influenzavirus B. The author mentions that 1 to 46% of the circulating viruses each season are caused by influenza B viruses. According to the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention, and World Health Organization in the U.S. that the possible solution to minimize the chance of a B-lineage mismatch is to include both B lineages in the influenza vaccines.

The article provides information on an audio interview conducted on December 9, 2020 with Doctors Eric Rubin, Lindsey R. Baden and Joshua A. Barocas about who should be first in line as Covid-19 vaccines are launched.

The article examines that spread of SARS-CoV-2 remains a Public Health Emergency of International Concern as physicians need to know about transmission, diagnosis, and treatment of Covid-19 is the subject of ongoing updates from infectious disease.

The article examines that continuing spread of SARS-CoV-2 remains a Public Health Emergency of International Concern as physicians need to know about transmission, diagnosis, and treatment of Covid-19 is the subject of ongoing updates from infectious disease.

An editorial is presented on the need for a booster to restore high antibody levels both to reduce infection with new variants and to minimize hospitalization and death. Topics include restore high antibody levels both to reduce infection with new variants and to minimize hospitalization and death; and emergence of the omicron variant has increased the urgency of these booster doses.

The article focuses on the study regarding the impact of preexposure prophylaxis for HIV. It states that there was a possibility of developing resistance tot the antiviral agents used in the HIV acquired during preexposure prophylaxis. It says that a management plan was needed when recommending preexposure prophylaxis which recognizes the intervention's effect on the sexual behavior and well-being of the patient.

The author discusses concerns about the optimal time to start antiretroviral therapy in asymptomatic patients. The topic has become a central controversy in the care of HIV patients since the introduction of antiretroviral agent zidovudine. Particular attention is paid to the results of a study published in this issue of the journal titled "Effect of early versus deferred antiretroviral therapy for HIV on survival."